CA3144307A1 - Methods of treating hiv in pediatric patients with rilpivirine - Google Patents

Methods of treating hiv in pediatric patients with rilpivirine Download PDF

Info

Publication number
CA3144307A1
CA3144307A1 CA3144307A CA3144307A CA3144307A1 CA 3144307 A1 CA3144307 A1 CA 3144307A1 CA 3144307 A CA3144307 A CA 3144307A CA 3144307 A CA3144307 A CA 3144307A CA 3144307 A1 CA3144307 A1 CA 3144307A1
Authority
CA
Canada
Prior art keywords
rilpivirine
hiv
acceptable salt
pharmaceutically acceptable
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3144307A
Other languages
English (en)
French (fr)
Inventor
Herta Crauwels
Simon VANVEGGEL
Veerle VAN EYGEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of CA3144307A1 publication Critical patent/CA3144307A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3144307A 2019-07-03 2020-07-03 Methods of treating hiv in pediatric patients with rilpivirine Pending CA3144307A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
US62/870,413 2019-07-03
US16/919,677 US20210000823A1 (en) 2019-07-03 2020-07-02 Methods of treating hiv
US16/919,677 2020-07-02
PCT/EP2020/068913 WO2021001568A1 (en) 2019-07-03 2020-07-03 Methods of treating hiv in pediatric patients with rilpivirine

Publications (1)

Publication Number Publication Date
CA3144307A1 true CA3144307A1 (en) 2021-01-07

Family

ID=71579550

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3144307A Pending CA3144307A1 (en) 2019-07-03 2020-07-03 Methods of treating hiv in pediatric patients with rilpivirine

Country Status (14)

Country Link
US (3) US20210000823A1 (enExample)
EP (2) EP3993799A1 (enExample)
JP (2) JP2022538338A (enExample)
KR (2) KR20220028049A (enExample)
CN (2) CN114126655A (enExample)
AU (2) AU2020300818A1 (enExample)
BR (2) BR112021026916A2 (enExample)
CA (1) CA3144307A1 (enExample)
IL (1) IL289457A (enExample)
JO (1) JOP20210347A1 (enExample)
MA (2) MA56449A (enExample)
MX (2) MX2022000060A (enExample)
PH (1) PH12021553288A1 (enExample)
WO (2) WO2021001508A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
JP2014500261A (ja) * 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
PT4070788T (pt) * 2015-06-30 2023-06-06 Gilead Sciences Inc Formulações farmacêuticas
US11065198B2 (en) * 2016-10-24 2021-07-20 Janssen Sciences Ireland Unlimited Company Dispersible compositions
CN110958883A (zh) * 2017-06-30 2020-04-03 Viiv保健公司 组合及其用途和疗法
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Also Published As

Publication number Publication date
US20210000823A1 (en) 2021-01-07
KR20220028048A (ko) 2022-03-08
CN114126655A (zh) 2022-03-01
MA56449A (fr) 2022-05-11
CN114080223A (zh) 2022-02-22
AU2020300818A1 (en) 2022-03-03
AU2020300033A1 (en) 2022-02-24
EP3993799A1 (en) 2022-05-11
BR112021026739A2 (pt) 2022-04-26
MA56453A (fr) 2022-05-11
MX2021015627A (es) 2022-04-25
PH12021553288A1 (en) 2022-08-01
WO2021001568A1 (en) 2021-01-07
JP2022538338A (ja) 2022-09-01
EP3993800A1 (en) 2022-05-11
MX2022000060A (es) 2022-04-18
US20240139186A1 (en) 2024-05-02
BR112021026916A2 (pt) 2022-05-10
KR20220028049A (ko) 2022-03-08
IL289457A (en) 2022-02-01
WO2021001508A1 (en) 2021-01-07
JP2022538449A (ja) 2022-09-02
CA3144534A1 (en) 2021-01-07
JOP20210347A1 (ar) 2023-01-30
US20220313693A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
Fabbiani et al. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)
AU2022266680A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
US20240139186A1 (en) Methods of treating hiv
Kuhlin et al. Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis
JP7791083B2 (ja) カボテグラビルおよびリルピビリンでｈｉｖを治療するための方法
Fulco et al. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents
CA3144534C (en) Methods of treating hiv in pediatric patients with rilpivirine
Fisher Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis
Landman et al. COPEDOL: a two-year observational study in pretreated HIV-1-infected patients switching to a dolutegravir-based regimen
HK40069556A (en) Methods of treating hiv in pediatric patients with rilpivirine
HK40069822A (en) Methods of treating hiv in pediatric patients with rilpivirine
Di Biagio et al. The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients
Kasserra et al. Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women
Slim et al. A Stable Switch From Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) to Dolutegravir/Lamivudine (DTG/3TC) in the Absence of Historical Resistance Records: Results From the Switch to Dovato in Patients Suppressed on Biktarvy (SOUND) Cohort
RU2840867C1 (ru) Способ лечения вич каботегравиром и рилпивирином
Verna et al. 553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
Johnson et al. A systematic review of the use of atazanavir in women infected with HIV-1
Citeroni et al. POS0662 PREDICTORS OF TOXICITY WITH HYDROXYCHLOROQUINE AND CHLOROQUINE USE: A SYSTEMATIC REVIEW
Psomas et al. Highlights of the Conference on Retroviruses and Opportunistic Infections, 12–16 February 2022, virtual
WO2023232838A1 (en) Bedaquiline for use in the treatment of leprosy
Brinson Potential Implications of Baseline Viral Load on the Relative Potency of First-line, NNRTI-Based Antiretroviral Therapy. 1: 542 doi: 10.4172/scientificreports. 542 Page 2 of 3 Volume 1• Issue 12• 2012 efficacy and safety of the original immediate-release (IR) and recently approved extended-release (XR) formulations of NVP in first-line therapy for treatment-naïve, HIV-infected patients (n= 1,011)[9]
Wittawatmongkol et al. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children
WO2020064980A1 (en) Methods of treating and preventing neuropsychiatric and/or neurocognitive complications in patients infected with hiv
US20220096487A1 (en) Methods for treating hiv with dolutegravir and lamivudine
Iacob et al. Long-Acting Antiretroviral Formulations: A New Perspective Aimed to Improve Adherence to HIV Therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240925

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241002

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20241211

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241211

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241211

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250602

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250603

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250603

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251001

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251202

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251202